CRPOF News and Press, Ceapro Inc From 01/10/23

EDMONTON, Alberta, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”) , a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic ind...

EDMONTON, Alberta, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”) , a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic ind...

Ceapro ( OTCQX:CRPOF ) said on Thursday it had received approval from Health Canada to begin Phase 1/2a study testing its drug, avenanthramide, as a potential anti-inflammatory product. This early-stage trial will enroll 96 subjects with dosages that may escalate from 30 mg ...

- Ceapro is pioneering approach with a natural product as a potential anti-inflammatory - Clinical study to be conducted with the Montreal Heart Institute led by MHI’s Montreal Health Innovations Coordinating Center (MHICC) EDMONTON, Alberta, Dec. 22, 2022 (GLOBE NEWSWIRE...

Ceapro press release ( OTCQX:CRPOF ): Q3 GAAP EPS of C$0.01. Revenue of C$3.85M (-14.8% Y/Y). For further details see: Ceapro GAAP EPS of C$0.01, revenue of C$3.85M

– R&D activities focused on the production of Avenanthramides pills for clinical trials and for scale-up of the PGX Technology – Q3 2022 sales of $3,845,000 vs $4,523,000 in Q3 2021 ; YTD sales increase 14% vs 2021 - $15,517,000 vs $13,633,000 ...

PGX processing unit to be installed at Agri-Food Discovery Place of University of Alberta Alginate and yeast beta glucan to be the first bio actives to be processed at this location EDMONTON, Alberta, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO;...

Findings from this collaborative project with the University of Alberta using a unique surgical methodology illustrate how PGX-processed carriers can successfully be uniformly loaded with a fat-soluble active ingredient to generate superior bioactive delivery systems Superior bi...

Summary Ceapro has been steadily building its core business. The company has developed a new technology that offers expansion into adjacent markets and product expansion. The stock sells at modest valuation relative to the revenue growth, profitability, cash generation and pro...

Ceapro press release ( OTCQX:CRPOF ): Q2 GAAP EPS of $0.02. Revenue of $5.5M (+25.0% Y/Y). For further details see: Ceapro GAAP EPS of $0.02, revenue of $5.5M